1. Home
  2. SPRO vs HTCR Comparison

SPRO vs HTCR Comparison

Compare SPRO & HTCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • HTCR
  • Stock Information
  • Founded
  • SPRO 2013
  • HTCR 2009
  • Country
  • SPRO United States
  • HTCR Japan
  • Employees
  • SPRO N/A
  • HTCR N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • HTCR EDP Services
  • Sector
  • SPRO Health Care
  • HTCR Technology
  • Exchange
  • SPRO Nasdaq
  • HTCR Nasdaq
  • Market Cap
  • SPRO 45.7M
  • HTCR 48.1M
  • IPO Year
  • SPRO 2017
  • HTCR 2022
  • Fundamental
  • Price
  • SPRO $0.83
  • HTCR $1.34
  • Analyst Decision
  • SPRO Buy
  • HTCR
  • Analyst Count
  • SPRO 4
  • HTCR 0
  • Target Price
  • SPRO $5.00
  • HTCR N/A
  • AVG Volume (30 Days)
  • SPRO 217.5K
  • HTCR 128.1K
  • Earning Date
  • SPRO 03-12-2025
  • HTCR 04-07-2025
  • Dividend Yield
  • SPRO N/A
  • HTCR 2.88%
  • EPS Growth
  • SPRO N/A
  • HTCR N/A
  • EPS
  • SPRO 0.06
  • HTCR 0.23
  • Revenue
  • SPRO $106,455,000.00
  • HTCR $30,290,930.00
  • Revenue This Year
  • SPRO N/A
  • HTCR $53.30
  • Revenue Next Year
  • SPRO N/A
  • HTCR N/A
  • P/E Ratio
  • SPRO $12.71
  • HTCR $5.98
  • Revenue Growth
  • SPRO 37.01
  • HTCR 47.63
  • 52 Week Low
  • SPRO $0.74
  • HTCR $0.55
  • 52 Week High
  • SPRO $1.89
  • HTCR $3.38
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 44.07
  • HTCR 42.19
  • Support Level
  • SPRO $0.82
  • HTCR $1.41
  • Resistance Level
  • SPRO $0.85
  • HTCR $1.60
  • Average True Range (ATR)
  • SPRO 0.05
  • HTCR 0.13
  • MACD
  • SPRO 0.01
  • HTCR -0.01
  • Stochastic Oscillator
  • SPRO 43.33
  • HTCR 2.50

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company. It provides software through two business units. The first business unit includes a customer experience management business that has been in existence for 12 years. The customer experience management platform includes marketing, sales, service and content management systems, as well as other tools and integrations, that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, its DX division, is a digital transformation business that provides customers with robotics process automation, process mining and task mining to accelerate the digital transformation of enterprises.

Share on Social Networks: